Risk factors and outcomes of Candida krusei bloodstream infection: A matched, case-control study

Journal of Infection

Volumn 66, Issue 3, 2013, Pages 278-284

  Schuster, Mindy G ^a   Meibohm, Anne ^b   Lloyd, Lisa ^c   Strom, Brian ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Statistical Consultants   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Candida krusei; Candidemia; Case control; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; FLUCONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BLOODSTREAM INFECTION; CANDIDEMIA; CASE CONTROL STUDY; CAUSE OF DEATH; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; FEMALE; FUNGAL COLONIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; LENGTH OF STAY; MALE; NEUTROPENIA; POST TREATMENT SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SPLENECTOMY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIFUNGAL AGENTS; BLOOD; CANDIDA; CANDIDEMIA; CASE-CONTROL STUDIES; CULTURE MEDIA; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEUTROPENIA; RISK FACTORS; SPLENECTOMY; SURVIVAL RATE;

EID: 84873256827     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.11.002     Document Type: Article

References (37)

1. Tortorano A.M., Kibbler C., Peman J., Bernhardt H., Klingspor L., Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006, 27:359-366.
2. Sipsas N.V., Lewis R.E., Rarrand J., Hachem R., Rolston K.V., Raad I., et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). Cancer 2009; Oct, 15:4745-4752.
3. Hajjeh R.A., Sofair A.N., Harrison L.H., Lyon G.M., Arthington-Skaggs B.A., Mirza S.A., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.
4. Pfaller M.A., Diekema D.I. Role of sentinel surveillance of candidaemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002, 40:3551-3557.
5. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravulconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39:3254-3259.
6. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
7. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996, 10:617-623.
8. Hachem R., Hanna H., Kontoyiannis D., Jiang Y., Raad I. The changing epidemiology of invasive candidiasis. Cancer 2008, 112:2493-2499.
9. Bodey G.P., Mardani M., Hanna H.A., Boktour M., Abbas J., Girgawy E., et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002, 112:380-385.
10. Pfaller M.A., Messer S.A., Moet G.J., Jones R.N., Castanheira M. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008-2009). Int J Antimicrob Agents 2011, 38:65-69.
11. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115-125.
12. Abbas J., Bodey G.P., Hanna H.A., Mardani M., Girgawy E., Abi-Said D., et al. Candida krusei fungemia: an escalating serious infection in immunocompromised patients. Arch Intern Med 2000, 160:2659-2664.
13. Hope W., Morton A., Eisen D.D.P. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002, 50:56-65.
14. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R., et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325:1274-1277.
15. Chow J.K., Golan Y., Ruthazer R., Karchmer A.W., Carmeli Y., Lichtenberg D., Chawla V., et al. Factors associated with candidemia caused by non-albicans candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008, 46:1206-1213.
16. Chen S.C., Marriott D., Playford E.G., Nguyen Q., Ellis D., Meyer W., Sorrell T.C., et al. Candidemia with uncommon Candida species; predisposing factors, outcome antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009, 15:662-669.
17. Rodriguez D., Almirante B., Cuenca-Estrella M., Rodríguez-Tudela J.L., Mensa J., Ayats J., et al. Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect 2010, 16:1676-1682.
18. Lortholary O., Desnos-Ollivier M., Sitbon K. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2010, 55:532-538.
19. Persons D.A., Laughlin M., Tanner D., Perfect J., Gockerman J.P., Hathorn J.W. Fluconazole and Candida krusei fungemia. N Engl J Med 1991, 325:113.
20. Abi-Said D., Anaissie O., Uzun I., Raad H., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different candida species. Clin Infect Dis 1997, 24:1122-1128.
21. Gleason T.G., May A.K., Caparelli D., Farr B.M., Sawyer R.G. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997, 132:1197-1202.
22. Shorr A.F., Lazaurs D.R., Sherner J.H., Jackson W.L., Morrel M., Fraser V.J., et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007, 35:1077-1083.
23. Slavin M.A., Sorrell T.C., Marriott D., Thursky K.A., Nguyen Q., Ellis D.H., et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010, 65:1042-1051.
24. Blot S., Janssens R., Claeys G., Hoste E., Buyle F., De Waele J.J., et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother 2006, 58:474-477.
25. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326:845-851.
26. Winston D.J., Chandrasekar P.H., Lazarus H.M., Goodman J.L., Silber J.L., Horowitz H., et al. Fluconazole prophylaxis for fungal infection in patients with acute leukemia: results of a randomized placebo-controlled, double blind, multicenter trial. Ann Intern Med 1993, 118:495-503.
27. Kunova A., Trupl J., Dluholucky S., Galova G., Krcméry V. Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clin Infect Dis 1995, 20:115-125.
28. Iwen P.C., Kelly D.M., Reed E.C., Hinrichs S.H. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995, 20:342-347.
29. Lin M.Y., Carmeli Y., Zumsteg J., Flores E.L., Tolentino J., Sreeramoju P., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia; a case-case-control study. Antimicrob Agents Chemother 2005, 49:4555-4560.
30. Merz W.G., Karp J.E., Schron D., Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol 1986, 24:581-584.
31. Wenzel R.P. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995, 20:1531-1534.
32. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer L., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
33. Kremery V., Barnes A.J. Non-albicans Candida spp. causing fungemia; pathogenicity and antifungal resistance. J Hosp Infect 2002, 50:243-260.
34. Collett D. Modeling binary data 2003, Chapman & Hall/CRC, New York, p. 93. 2nd ed.
35. Zaoutis T.E., Prasad P.A., Localio A.R., Coffin S.E., Bell L.M., Walsh T.J., et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010, 51(5):e38-e45.
36. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186.
37. Goldman M., Pottage J.C., Weaver D.C. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine 1993, 72:143-150.